Pifeltro OverviewDoravirine (MK-1439) is a non-nucleoside reverse transcriptase inhibitor developed by Merck & Co. for use in the treatment of HIV/AIDS. In August 2018, the FDA approved doravirine under the product name Pifeltro, and in a combination tablet, doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo). References ^ Collins, Simon; Horn, Tim. "The Antiretroviral Pipeline" (PDF). Pipeline Report. p.10. Archived from the original (PDF) on 11 March 2016. Retrieved ...
Read more Pifeltro Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Doravirine
Recent Pifeltro Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Tablet: 100mg
NDC Database Records for Pifeltro: (1 result)Sorted by National Drug Code
- 0006-3069 Pifeltro 100 mg Oral Tablet, Film Coated by Merck Sharp & Dohme Corp.
Other drugs which contain Doravirine or a similar ingredient: (3 results)
- DELSTRIGO Doravirine + Lamivudine + Tenofovir Disoproxil Fumarate
- DORAVIRINE + LAMIVUDINE + TENOFOVIR DISOPROXIL FUMARATE